Trial Profile

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etakafusp alfa (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Head and neck cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Asher Biotherapeutics

10 Sep 2025 Status changed from recruiting to active, no longer recruiting.
09 May 2024 Planned End Date changed from 1 Oct 2025 to 1 May 2027.
09 May 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Aug 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com